title: Molecular biology and neurosurgery in the third millennium.
abstract: The application of techniques in molecular biology to human neurosurgical conditions has led to an increased understanding of disease processes that affect the brain and to novel forms of therapy that favorably modify the natural history of many of these conditions. Molecular strategies are currently being either used or sought for brain tumors, stroke, neurodegenerative diseases, vascular malformations, spinal degenerative diseases, and congenital malformations of the central nervous system. Considering that the structure of deoxyribonucleic acid was ascertained by Watson and Crick as recently as 1953, the progress that has been made to implement molecular medicine in clinical practice has been meteoric. More than 2000 patients have been treated in approved gene therapy trials throughout the world. Many of these patients have been treated for neurological diseases for which conventional medical therapies have been of limited utility. As part of this continuing series on advances in neurosurgery in the third millennium, we first reflect on the history of the nascent field of molecular biology. We then describe the powerful techniques that have evolved from knowledge in this field and have been used in many publications in Neurosurgery, particularly within the past decade. These methods include commonly used techniques such as advanced cytogenetics, differential display, microarray technology, molecular cell imaging, yeast two-hybrid assays, gene therapy, and stem cell utilization. We conclude with a description of the rapidly growing field of bioinformatics. Because the Human Genome Project will be completed within 5 years, providing a virtual blueprint of the human race, the next frontier (and perhaps our greatest challenge) will involve the development of the field of "proteomics," in which protein structure and function are determined from the deoxyribonucleic acid blueprint. It is our conviction that neurosurgeons will continue to be at the forefront of the treatment of patients with neurological diseases using molecular strategies, by performing essential research leading to increased understanding of diseases, by conducting carefully controlled studies to test the effects of treatments on disease processes, and by directly administering (by neurosurgical, endovascular, endoscopic, or stereotactic means) the treatments to patients.
authors.forename: J T
authors.initials: JT
authors.lastname: Rutka
authors.forename: M
authors.initials: M
authors.lastname: Taylor
authors.forename: T
authors.initials: T
authors.lastname: Mainprize
authors.forename: A
authors.initials: A
authors.lastname: Langlois
authors.forename: S
authors.initials: S
authors.lastname: Ivanchuk
authors.forename: S
authors.initials: S
authors.lastname: Mondal
authors.forename: P
authors.initials: P
authors.lastname: Dirks
mesh_terms: D003582:Cytogenetics / Q000639:trends; D005544:Forecasting; D015316:Genetic Therapy / Q000639:trends; D006801:Humans; D008967:Molecular Biology / Q000639:trends*; D009493:Neurosurgery / Q000639:trends*